Article
The hexosamine biosynthesis pathway is a targetable liability in lung cancers with concurrent KRAS and LKB1 mutations
2020-04-14
Abstract excerpt
In non–small cell lung cancer (NSCLC), concurrent mutations in the oncogene KRAS and the tumor suppressor STK11 encoding the kinase LKB1 result in aggressive tumors prone to metastasis but with liabilities arising from reprogrammed metabolism. We previously demonstrated perturbed nitrogen metabolism and addiction to an unconventional pathway of pyrimidine synthesis in KRAS/LKB1 co-mutant (KL) cancer cells. To ga...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- f2105e45-7925-54ef-bef7-12e72ff45c11
- DOI
- 10.1101/2020.04.13.039669